Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia
Gege Gui(Johns Hopkins University), Christopher S. Hourigan(National Heart Lung and Blood Institute), Steven M. Devine(National Marrow Donor Program), Kristin Page(Medical College of Wisconsin), Antonio Jiménez(University of Miami), Zoë C. Wong(National Institutes of Health), Pranay S. Hegde(National Institutes of Health), Yi‐Bin Chen(Massachusetts General Hospital), Marcos de Lima(The Ohio State University), Devdeep Mukherjee(National Institutes of Health), Evan C. Chen(Dana-Farber Cancer Institute), Firas El Chaer(The University of Texas MD Anderson Cancer Center), Georgia Andrew(National Institutes of Health), Laura W. Dillon(Institute of Cancer Research), Wael Saber(Medical College of Wisconsin), Stephen R. Spellman(National Marrow Donor Program), Partow Kebriaei(The University of Texas MD Anderson Cancer Center), Sunil Iyer(University of Miami), Mark R. Litzow(Mayo Clinic in Arizona), Jeffery J. Auletta(Nationwide Children's Hospital), Scott L. Zeger(Johns Hopkins University), Adam Corner(Bio-Rad (United States)), Niveditha Ravindra(National Institutes of Health)
Cited by 10
Related Papers
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k